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Abstract 
Background: To evaluate the Door to needle time and 
its impact on successful thrombolysis . 
Methods : In this  cross sectional study all patients 
admitted with Acute Myocardial Infarction (AMI), who 
were candidates for fibrinolysis, were included. 
Streptokinase 1.5 million units i.v was given over one hour 
to all the patients. Door to needle time was calculated. 
Successful thrombolysis was considered as resolution of 
chest pain with 70 % ST-segment resolution 60–90 minutes 
after thrombolysis. 
Results : Ninety four  patients with acute myocardial 
infarction eligible for thrombolysis were given 
intravenous streptokinase.Majority (87.2%)were male. 
Successful thrombolysis was attained in 62.9% ,among 
those who received streptokinase within 30 minutes of 
onset of pain and in 16.7%  of those who received 
streptokinase after more than 30 minutes  
Conclusion: Timing of streptokinase infusion after 
first medical contact is an important predictor of successful 
thrombolysis. 
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Introduction 
      Fibrinolytic therapy (FT) has reduced mortality 
following acute myocardial infarction (AMI). The 
Grampian Region Early Anistreplase Trial (GREAT) 
showed that delaying thrombolytic treatment by 1 h 
increases the hazard ratio of death by 20%, equivalent 
to the loss of 43/1000 lives within the next 5 years 
(95% CI 7-88, P = 0.012). Delaying thrombolytic 
treatment by 30 minutes reduces the average 
expectation of life by approximately  1 year. The 
American College of Chest Physicians (ACCP) 
guidelines recommend that for patients with acute MI 
who are candidates for fibrinolytic therapy, the 
therapy should be administered within 30 min of 
arrival to the hospital or first contact with the health-
care system. 1  
     Early resolution of ST-segment elevation has been 
demonstrated to be a simple and useful predictor of 
final infarct size, left ventricular function, and clinical 
outcomes after both thrombolytic and coronary 
interventional approaches.2Thrombolytic therapy for 
acute myocardial infarction reduces fatality and 
improves clinical outcomes. However, in 60% of 
patients the treatment does not restore perfusion in the 
myocardium at risk, and such failure indicates a worse 
prognosis. Reperfusion therapy in STEMI is the most 
important component of treatment, as it strongly 
influences short- and long-term patient outcome. The 
main objective of healthcare providers should be to 
achieve at least 75% of reperfusion therapy applied to 
patients of STEMI in a timely manner, and preferably 
within 30 minutes according to the guidelines.3 
 
Patients and Methods 
     In this descriptive study all patients  who were 
thrombolysed for AMI at Armed Forces Institute of 
Cardiology/National Institute of Heart Diseases, 
Rawalpindi, from July 2, 2011 to October 10, 2011 who 
were candidates for fibrinolysis, were enrolled. 
Streptokinase 1.5 million units i.v given over 1 hour 
was the fibrinolytic agent used in all the patients. Door 
to needle time was calculated by the medical 
officer/senior nurse on duty managing the patient in 
emergency ward or the coronary care unit. Successful 
thrombolysis was considered as resolution of chest 
pain with 70 % ST-segment resolution 60–90 minutes 
after thrombolysis. Patients presenting with chest pain 
of less than 12 hr duration, exhibiting ECG ST segment 
elevation of 2 mm in two contiguous chest leads and 1 
mm elevation in limb leads and patients who had no 
contraindication to streptokinase, were included. 
 
Results 
     Ninety four patients with acute myocardial 
infarction during the period were thrombolyzed. 
Majority (87.2%) were male with a mean age of 58.9 
years. Interior wall infarction was seen in 38.3%. In 
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74.5% door to needle time was upto 30 minutes (Table 
1). Successful thrombolysis was achieved  in those 
who were thrombolysed upto half an hour (62.9%) and 
had a duration of pain less than 6 hours(57.1%) (Table 
2). Hypotension was registered in 40.4%( Table 3) 
 
Table 1 : Baseline characterisitics of patients 
(n=94) 
Characteristic No(%) 
Risk Factors 
Hypertension  34(36.2) 
Diabetes 20(21.3) 
Smoking 30(31.9) 
Type of Myocardial Infarction 
Anterior wall 36(38.3) 
Anteroseptal wall 8(8.5) 
Anterolateral wall 10(10.6) 
Lateral wall 4(4.3) 
Inferior wall 20(21.2) 
Posteroinferior wall 6(6.4) 
Inferior wall with RV extension 10(10.6) 
Door to Needle Time 
Less than 30 minutes 70( 74.5) 
More than 30 minutes 24(25.5) 
 
Table 2: Patients characteristics in relation 
to successful thrombolysis 
Variable Total Successful 
Thrombolysis 
Failure of 
Thrombolysis 
p- 
value 
Total pts given 
Streptokinase 
94 48 (51.1%) 46 (48.9%)  
Male 
Female 
82 
12 
44 (53.7%) 
4 (33.3%) 
38 (46.3%) 
8 (66.6%) 
0.22
71 
Hypertension 34 20 (58.8%) 14 (41.2%) 0.22
28 
Smoking 30 18 (60.0%) 12 (40.0%) 0.27
32 
Diabetes 20 09 (45.0%) 11 (55.0%) 1.00
0 
Anterior MI 36 19 (52.8%) 17 (47.2%) 0.67
38 
Inferior MI 
(incl Posterior 
and RV infarct) 
36 20 (55.6%) 16 (44.4%) 0.53
01 
Anteroseptal 
MI 
8 5 (62.5%) 3 (37.5%) 0.71
48 
Anterolateral 
MI 
10 4 (40.0%) 6 (60.0%) 0.51
89 
Door to needle 
time 
< or = 30 min 
> 30 min 
 
 
70 
24 
 
 
44 (62.9%) 
4 (16.7%) 
 
 
26 (37.1%) 
20 (83.7%) 
 
 
0.00
01 
Pain Duration 
< 6hrs 
> 6hrs 
 
56 
38 
 
32 (57.1%) 
16 (42.1%) 
 
24 (42.9%) 
22 (57.9%) 
 
0.20
73 
Table 3: Thrombolytic Therapy-Major Side 
Effects 
Hypotension 40.4%(n=38) 
Ventricular 
Tachycardia/ 
Idioventricular Rhythm 
12.7%(n=12) 
Heart Block 18.1%(n=17) 
Major Bleed 3.2%(n=3) 
Death 4.2%(n=4) 
 
Discussion 
     This study shows the importance of early 
thrombolysis in getting the success in saving 
myocardium. No other factor including the duration of 
chest pain could gain statistical significance in terms of 
successful thrombolysis.3Several modes of reperfusion 
therapy for evolving Myocardial Infarction (MI) have 
been developed which differ in terms of effectiveness, 
complexity and cost.4Currently, the most relevant 
treatment options are: SK (1.5 MU over 1 hour), 
reteplase (2 boluses of 10 MU), and alteplase (tissue 
plasminogen activator, t-PA, 100 mg over 1.5 hour) 
and immediate angioplasty.5 Streptokinase is the least 
costly treatment option while direct angioplasty is 
expensive and complex. .6 Treatment of acute STEMI 
with thrombolytic therapy showed greater mortality 
reduction. Thrombolytic therapy with SK and other 
agents reduces mortality and is now well accepted as 
the mainstay of revascularisation options for most 
patients after an acute myocardial infarction.7-9 
         Coronary atherosclerosis is a diffuse process with 
segmental lesions called coronary plaques. The plaque 
ruptures, exposing the endothelial lining, and allowing 
prothrombotic enzymes and molecular triggers to mix 
with the blood. Platelets are activated, and the 
coagulation cascade is amplified resulting in a 
thrombus that occludes the vessel, preventing the 
circulation of oxygenated blood. Irreversible ischemia-
induced myocardial necrosis may occur within 20-60 
minutes of occlusion. The mainstay of treatment is 
reperfusion therapy through administration of 
fibrinolytics (pharmacologic reperfusion) or primary 
percutaneous coronary intervention (PCI) (mechanical 
reperfusion).10 
       The intracoronary infusion of SK will produce 
lysis of the occluding thrombus in up to 80% of 
patients. The SK regimen (1.5 MU/60 minutes) has 
remained unchanged for the past 20 years in patients 
with STEMI due to fear of hypotension (a specific 
effect of this thrombolytic agent) and of haemorrhagic 
complications.11 
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    In myocardial infarction each passing minute leads 
to progression of myocardial muscle damage thus 
conferring advantage to early thrombolysis. The 
American College of Chest Physicians (ACCP) 
guidelines recommend that for patients with acute MI 
who are candidates for fibrinolytic therapy, the 
therapy should be administered within 30 min of 
arrival to the hospital or first contact with the health-
care system 1 
      Most guidelines recommend a door-to-needle time 
of less than 30 minutes but it is difficult  to achieve this 
in most of the  patients. 12 A study conducted by Zed et 
al  at the Vancouver General Hospital showed that a 
door-to-needle time of <30 min was achieved in only 
24.3%.13 In contrast in present  study 74.5% of the 
patient were thrombolyzed within 30 minutes of 
arrival. This high rate was mainly due to prompt 
recognition of the diagnosis of myocardial infarction 
by taking a quick history and taking an ECG within 5 
minutes of patients arrival to the emergency setting 
and quickly sending the patient to the appropriate 
ward for initiation of thrombolysis. Majority (62.9%) of 
these patients were then able to achieve successful 
thrombolysis. 
 
Conclusion 
Early recognition of myocardial infarction and then 
early thrombolysis are important factors, resulting in a 
successful thrombolysis. 
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